Loading...

Protagonist Therapeutics, Inc.

PTGX•NASDAQ
Healthcare
Biotechnology
$100.00
$-2.62(-2.55%)
U.S. Market opens in 47h 44m

Protagonist Therapeutics, Inc. (PTGX) Stock Overview

Explore Protagonist Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap6.4B
P/E Ratio-48.65
EPS (TTM)$-2.05
ROE-0.20%
Fundamental Analysis

AI Price Forecasts

1 Month$102.10
3 Months$114.20
1 Year Target$99.10

PTGX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Protagonist Therapeutics, Inc. (PTGX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 47.14, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $99.10.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -48.65 and a market capitalization of 6.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.55%
5-Day Change
-5.28%
1-Month Change
-0.39%
3-Month Change
20.34%
6-Month Change
33.58%
Year-to-Date (YTD) Change
14.50%
1-Year Change
122.97%
3-Year Change
321.05%
5-Year Change
237.38%
All-Time (Max) Change
754.70%

Contact Information

https://www.protagonist-inc.com
510 474 0170
7707 Gateway Boulevard, Newark, CA, 94560-1160

Company Facts

124 Employees
IPO DateAug 11, 2016
CountryUS
Actively Trading

Frequently Asked Questions